September 12, 2024 | CME, Impetus Digital, Online medical education, Perks of virtual, Sustainability, Virtual training, carbon neutral, digital training, healthcare trends, med ed, medical education, professional development, reduce carbon footprint, sustainable medical education, virtual med ed
Discover how replacing in-person meetings with virtual alternatives can significantly cut carbon emissions and support environmental initiatives. Our latest video highlights the crucial role of virtual meetings in reducing the ecological impact of conferences. Join us in fostering a greener future!
Explore the environmental benefits of virtual meetings in our ninth video from the “Perks of Virtual Medical Education” series. Learn how shifting from in-person to virtual meetings can significantly reduce carbon emissions and support sustainability efforts.
9. The Environmental Footprint is Much Smaller with Virtual vs. In-Person Meetings The shift towards virtual meetings is not only a matter of convenience or cost but also a significant environmental decision. National and international in-person meetings often involve extensive travel that contributes to large carbon footprints. By incorporating virtual meetings, organizations can drastically cut down emissions associated with air travel and ground transportation. As the environmental movement gains momentum, and the pharmaceutical industry begins to embrace more sustainable practices, the preference for virtual participation continues to grow. Participants appreciate the option to engage from anywhere without the environmental cost of travel, and it is likely that such expectations will only increase in the future.
For more insights into how virtual meetings contribute to sustainability in medical education and beyond, visit our blog: https://www.impetusdigital.com/2020/09/17/top-10-reasons-why-virtual-collaboration-and-medical-education-will-persist-in-the-new-normal/
Enhance your sustainable engagement strategies with Impetus Digital:
Stay connected for more sustainable practices in medical education:
This content was provided by Impetus Digital
Company Details
Latest Content from Impetus Digital
In recent years, social media has evolved into an essential part of Pharma operations, for better or worse.
Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson’s community catalyzed the founding of Charco and how #innovative medical devices and software can improve…
Dr. Joshua Liu, Co-founder & CEO of SeamlessMD, explores how technology and “Digital Care Journeys” can help hospitals reduce the surgical backlog for high-volume procedures like hip and knee replacements,…
Virtual engagement experts helping life science companies have ongoing conversations with their customers through our best-in-class online collaboration tools. Best-In-Class CollaborationTechnology Impetus Digital provides two turn-key software solutions through the Impetus…
Lucy Jung, CEO & Founder of Charco Neurotech, shares how meeting members of the Parkinson’s community catalyzed the founding of Charco and how #innovative medical devices and software can improve…
About the AwardToronto, ON, December 15, 2022 — PM360, a leading trade magazine for marketing decision-makers in the pharmaceutical, biotech, medical device, and diagnostics industries, has named Impetus Digital’s Virtual…
Dr. Ittai Dayan, Co-founder & CEO of Rhino Health, shares how his company is transforming the way healthcare AI solutions are created, adopted and measured. He will also explore how…
In this customer story, we describe the methodology and results of our client’s ongoing Virtual Steering Committee & Peer Influence program.
Tip #8 – Do you make sure to have a host for all your virtual events? Check our top 10 tips to increase engagement during virtual events: https://www.impetusdigital.com/2021/03/25/top-10-tips-to-increase-engagement-during-virtual-events/
Savva Kerdemelidis, Founder & CEO of Crowd Funded Cures, explores the concepts of interventional pharmacoeconomics and pay-for-success contracts to fund new uses for off-patent drugs and other unmonopolizable therapies.
